Moderna, Inc. $MRNA Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its position in Moderna, Inc. (NASDAQ:MRNA) by 1.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,846,666 shares of the company’s stock after selling 247,458 shares during the period. Baillie Gifford & Co. owned approximately 5.59% of Moderna worth $564,299,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Parkside Financial Bank & Trust raised its position in Moderna by 19.0% in the second quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock worth $65,000 after acquiring an additional 375 shares in the last quarter. Probity Advisors Inc. boosted its position in shares of Moderna by 2.6% during the 2nd quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock valued at $411,000 after purchasing an additional 377 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock worth $1,806,000 after purchasing an additional 408 shares in the last quarter. Rothschild Investment LLC raised its holdings in shares of Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after purchasing an additional 446 shares in the last quarter. Finally, 180 Wealth Advisors LLC lifted its stake in Moderna by 2.8% during the second quarter. 180 Wealth Advisors LLC now owns 23,928 shares of the company’s stock valued at $660,000 after purchasing an additional 642 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Five‑year follow‑up Phase IIb results for Moderna and Merck’s personalized melanoma vaccine show a large reduction in recurrence/death (~49% risk reduction when combined with Keytruda), supporting the thesis that oncology programs could materially re‑rate Moderna’s growth story. MRNA & MRK’s Personalized Cancer Therapy Delivers Strong 5-Year Data
• Positive Sentiment: Multiple outlets report the melanoma vaccine showed durable protection at 5 years and that early clinical readouts have driven a rally and momentum toward a 52‑week high — a near‑term positive for sentiment and potential re‑rating if further trials succeed. mRNA cancer vaccine shows protection at 5-year follow-up
• Positive Sentiment: Press coverage highlights promising melanoma vaccine data and positions oncology and personalized medicine as the company’s path to rebuild top‑line growth after the COVID vaccine era. Moderna’s Skin Cancer Vaccine Is Looking Seriously Promising
• Neutral Sentiment: Market context: broader market moves and sector rotation helped magnify Moderna’s stock swings this week; coverage of the rally and technical momentum is mixed with reminders that biotech remains volatile. MarketBeat Week in Review – 01/19 – 01/23
• Negative Sentiment: CEO comments that Moderna will curb investment in new late‑stage infectious‑disease vaccine trials because of growing U.S. anti‑vaccine backlash introduce strategic and political risk — potentially capping near‑term vaccine revenue upside and raising uncertainty about the company’s vaccine pipeline plans. Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV
• Negative Sentiment: Coverage emphasizes the “pullback” from new vaccine trials and rising anti‑vax sentiment as a drag on the company’s ability to monetize respiratory vaccines going forward — a catalyst that can offset optimism from oncology data and prompt profit‑taking. Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

Moderna Stock Down 6.0%

Shares of Moderna stock opened at $48.78 on Friday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $55.20. The stock has a market cap of $19.06 billion, a PE ratio of -6.04 and a beta of 1.17. The business has a fifty day simple moving average of $31.77 and a 200-day simple moving average of $28.81.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $893.29 million. During the same period in the prior year, the business earned $0.03 EPS. The business’s revenue for the quarter was down 45.4% on a year-over-year basis. Analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the transaction, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on MRNA. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Moderna in a research report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Berenberg Bank set a $28.00 price target on Moderna in a research report on Monday, November 17th. Leerink Partners lifted their price target on Moderna from $15.00 to $18.00 and gave the stock an “underperform” rating in a research note on Friday, November 21st. Finally, Citigroup restated a “neutral” rating on shares of Moderna in a report on Monday. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $30.36.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.